NRX Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by NRX Pharmaceuticals, Inc. on February 1, 2024, regarding events occurring on January 19, 2024. The Company is incorporated in Delaware and its securities trade on The Nasdaq Stock Market LLC under the symbols NRXP (Common Stock) and NRXPW (Warrants).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status rather than financial performance.
Material Changes
The primary material change reported is the transfer of the Company's listing from The Nasdaq Global Market to The Nasdaq Capital Market. This transfer was approved by Nasdaq and became effective at the opening of business on January 19, 2024. This action followed a prior exception granted on January 23, 2024, allowing the Company time to demonstrate compliance with Nasdaq Listing Rule 5450(a)(1).
Outlook, Risks, and Management Commentary
The filing confirms the successful completion of the listing transfer process. The Company had previously secured an exception to demonstrate compliance with listing standards until April 16, 2024, subject to conditions including the timely filing of transfer documentation. No specific forward-looking guidance, new risks, or unusual items were disclosed in this specific report.
Key Facts for Investor Verification
- Listing Status: Securities are now listed on The Nasdaq Capital Market as of January 19, 2024.
- Compliance Deadline: The Company must demonstrate compliance with Nasdaq Listing Rule 5450(a)(1) by April 16, 2024.
- Trading Symbols: Common Stock (NRXP) and Warrants (NRXPW) continue to trade on Nasdaq.
- Financial Data: No financial metrics are included in this filing; investors should refer to the most recent 10-K or 10-Q for financial performance.